Today the company said its experimental drug helped reduce symptoms of major depressive disorder (MDD) and insomnia in a late-stage trial when given along with commonly used antipsychotic treatments.
Today the company announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.
The company announced its plans to revise its financial statements in March, citing “material weakness in its internal control over financial reporting”.
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s.
Consumers generally are not fans of risk. But when consumers become patients, the game changes.
Johnson & Johnson is continuing its buying activity in the skin disease space, announcing Tuesday plans to purchase Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, and its bispecific antibody NM26 for $1.25 billion in cash.